Randomized, Open, Prospective, Phase II Clinical Trial of Doxorubicin (DOXO) vs. Trabectedin Plus Doxo in the First-Line Treatment of Patients (PTS) with Advanced Non-Operable and/or Metastatic Soft Tissue Sarcomas (STS): Geis-20 Study

Author(s):

J. Martin Broto ◽

X. Garcia Del Muro ◽

A. Lopez-Pousa ◽

R. Las De Penas ◽

J. Maurel ◽

...

Keyword(s):

Clinical Trial ◽

Soft Tissue ◽

Phase Ii ◽

Soft Tissue Sarcomas ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

Prospective Phase ◽

Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-016-2127-2 ◽

2016 ◽

Vol 142 (6) ◽

pp. 1315-1323 ◽

Cited By ~ 2

Author(s):

Ying-Chun Xu ◽

Qi Xu ◽

Jun-Jian Li ◽

Xiao-Feng Gu ◽

Xiao-Lin Lin ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Gastrointestinal Cancer ◽

Killer Cell ◽

Stage Iv ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

1404P Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1513 ◽

2021 ◽

Vol 32 ◽

pp. S1058

Author(s):

J. Wang ◽

T. Wu ◽

Y-G. Hong ◽

S-X. Luo ◽

N. Li ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.9033 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 9033-9033

Author(s):

A. Lopez-Pousa ◽

J. Buesa ◽

A. Casado ◽

J. Garcia Del Muro ◽

A. Poveda ◽

...

Keyword(s):

Soft Tissue ◽

Phase Ii ◽

Phase Ii Trial ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

Prolonged Infusion ◽

First Line ◽

A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.10072 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10072-10072 ◽

Cited By ~ 3

Author(s):

A. Lopez-Pousa ◽

B. Bui Nguyen ◽

X. Garcia del Muro ◽

J. Martin Broto ◽

C. Balañá ◽

...

Keyword(s):

Soft Tissue ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

First Line ◽

New Formulation ◽

56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2020.08.034 ◽

2020 ◽

Vol 31 ◽

pp. S262-S263

Author(s):

J. Zhou ◽

J. Fan ◽

G. Shi ◽

X. Huang ◽

D. Wu ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Intrahepatic Cholangiocarcinoma ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.9033 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 9033-9033 ◽

Author(s):

A. Lopez-Pousa ◽

J. Buesa ◽

A. Casado ◽

J. Garcia Del Muro ◽

A. Poveda ◽

...

Keyword(s):

Soft Tissue ◽

Phase Ii ◽

Phase Ii Trial ◽

Soft Tissue Sarcomas ◽

Line Treatment ◽

Prolonged Infusion ◽

First Line ◽

Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: Interim analysis of prospective phase II clinical trial

Annals of Oncology ◽

10.1093/annonc/mdy299.026 ◽

2018 ◽

Vol 29 ◽

pp. viii585-viii586 ◽

Author(s):

M. Spalek ◽

H.M. Kosela Paterczyk ◽

A. Borkowska ◽

M. Wagrodzki ◽

A. Cieszanowski ◽

...

Keyword(s):

Clinical Trial ◽

Soft Tissue ◽

Phase Ii ◽

Interim Analysis ◽

Soft Tissue Sarcomas ◽

Phase Ii Clinical Trial ◽

Hypofractionated Radiotherapy ◽

High Grade ◽

Prospective Phase

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

Cancer Communications ◽

10.1002/cac2.12119 ◽

2020 ◽

Vol 40 (12) ◽

pp. 711-720

Author(s):

Bo Zhang ◽

Ling Qi ◽

Xi Wang ◽

Jianping Xu ◽

Yun Liu ◽

...

Keyword(s):

Clinical Trial ◽

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

1131 POSTER Addition of CPG 7909 to taxane/platinum regimen for first-line treatment of unresectable NSCLC improves objective response in phase II clinical trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81425-9 ◽

2005 ◽

Vol 3 (2) ◽

pp. 326-327 ◽

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Objective Response ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line ◽

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial

Annals of Translational Medicine ◽

10.21037/atm-20-2990 ◽

2020 ◽

Vol 8 (17) ◽

pp. 1047-1047

Author(s):

Zhenyu Hou ◽

Keyun Zhu ◽

Xuejiao Yang ◽

Ping Chen ◽

Wei Zhang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

First Line ◽